Current industrial practices of assessing permeability and P-glycoprotein interaction
暂无分享,去创建一个
Yong-Hae Han | S. Chong | P. Balimane | Yong-Hae Han | Saeho Chong | Praveen V. Balimane | Yong‐Hae Han
[1] J. Dressman,et al. Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women , 1990, Pharmaceutical Research.
[2] T. Kissel,et al. Heterogeneity in the human intestinal cell line Caco-2 leads to differences in transepithelial transport , 1995 .
[3] Jiunn H. Lin,et al. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. , 2003, Advanced drug delivery reviews.
[4] B. Aungst,et al. The Influence of Donor and Reservoir Additives on Caco-2 Permeability and Secretory Transport of HIV Protease Inhibitors and Other Lipophilic Compounds , 2000, Pharmaceutical Research.
[5] S. Chong,et al. A combined cell based approach to identify P-glycoprotein substrates and inhibitors in a single assay. , 2005, International journal of pharmaceutics.
[6] J. Hochman,et al. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.
[7] K. Brouwer,et al. Secretory Transport of Ranitidine and Famotidine across Caco-2 Cell Monolayers , 2002, Journal of Pharmacology and Experimental Therapeutics.
[8] S. Binkley,et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. , 1999, The Journal of pharmacology and experimental therapeutics.
[9] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[10] P. Artursson. Cell cultures as models for drug absorption across the intestinal mucosa. , 1991, Critical reviews in therapeutic drug carrier systems.
[11] A. Ungell. Caco-2 replace or refine? , 2004, Drug discovery today. Technologies.
[12] A. Avdeef,et al. Physicochemical profiling (solubility, permeability and charge state). , 2001, Current topics in medicinal chemistry.
[13] E. L. Volk,et al. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.
[14] A. Avdeef,et al. PAMPA--a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa(flux)--optimized design (pOD-PAMPA). , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[15] M. Morris,et al. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. , 2004, Molecular pharmacology.
[16] R A Morrison,et al. Current methodologies used for evaluation of intestinal permeability and absorption. , 2000, Journal of pharmacological and toxicological methods.
[17] Ryuichi Matsuno,et al. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. , 2004, Bioorganic & medicinal chemistry.
[18] E. Kerns,et al. High throughput physicochemical profiling for drug discovery. , 2001, Journal of pharmaceutical sciences.
[19] T. Kissel,et al. Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. , 2004, Journal of pharmaceutical sciences.
[20] A. Herrmann,et al. Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). , 2003, The Biochemical journal.
[21] F H Hausheer,et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] P. Artursson,et al. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.
[23] Jiunn H. Lin,et al. Role of P-Glycoprotein in Pharmacokinetics , 2003, Clinical pharmacokinetics.
[24] A. Nomeir,et al. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. , 2001, International journal of pharmaceutics.
[25] Mark M. Roden,et al. Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.
[26] B. Rothen‐Rutishauser,et al. Cell cultures as tools in biopharmacy. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[27] S. Chong,et al. In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of in Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System , 2004, Pharmaceutical Research.
[28] P. Augustijns,et al. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. , 2003, Journal of pharmaceutical sciences.
[29] W. Sadee,et al. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[30] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[31] James E Polli,et al. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[32] J. Polli,et al. Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.
[33] T. Uchiumi,et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.
[34] Yuichi Sugiyama,et al. Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.
[35] Lawrence X. Yu,et al. Effect of common excipients on Caco-2 transport of low-permeability drugs. , 2001, Journal of pharmaceutical sciences.
[36] A. Avdeef,et al. PAMPA--a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DS-PAMPA models. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[37] Joseph W. Polli,et al. Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor , 1999, Pharmaceutical Research.
[38] I. Hidalgo,et al. Assessing the absorption of new pharmaceuticals. , 2001, Current topics in medicinal chemistry.
[39] S. Chong,et al. Cell culture-based models for intestinal permeability: a critique. , 2005, Drug discovery today.
[40] W. Rubas,et al. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. , 1996, Journal of pharmaceutical sciences.
[41] K. Hillgren,et al. In vitro systems for studying intestinal drug absorption , 1995, Medicinal research reviews.
[42] Li Di,et al. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. , 2004, Journal of pharmaceutical sciences.
[43] D. Greenblatt,et al. Rapid Assessment of P-Glycoprotein Inhibition and Induction in Vitro , 2003, Pharmaceutical Research.
[44] B. Jarvis,et al. Fexofenadine , 2000, Drugs.
[45] J. Dressman,et al. Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women , 1993, Pharmaceutical Research.
[46] Pratik Saha,et al. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[47] A. Florence,et al. Effects of Some Non‐ionic Surfactants on Transepithelial Permeability in Caco‐2 Cells , 2000, The Journal of pharmacy and pharmacology.
[48] K Gubernator,et al. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.
[49] Y. Sawada,et al. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. , 1992, Journal of hepatology.
[50] Li Di,et al. High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.
[51] R. Borchardt,et al. Isolation and Characterization of Caco-2 Subclones Expressing High Levels of Multidrug Resistance Protein Efflux Transporter , 2003, Pharmaceutical Research.
[52] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.